The present invention relates to exosomes isolated from dermal papilla progenitor cells, specifically, the exosomes isolated from the dermal papilla progenitor cells which are excellent in prevention, improvement and treatment of hair loss (alopecia) and are also excellent in terms of skin improvement and wound healing effects, as well as various uses thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The present disclosure relates to in vitro models of biliary atresia obtained by culturing of human liver organoids and/or mini-bile ducts and exposing the liver organoids and/or mini-bile ducts to biliatresone. The present disclosure also provides methods of preparation of the in vitro models of biliary atresia, and applications thereof.

The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.

Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.

The present invention is related to a biochip and production method thereof. The biochip comprises a carrier, a cell or tissue culture area deposited on the carrier, and a sensor area deposited on the carrier adjacent and fluidly communicating with the cell or tissue culture area. A containing space is contained in the cell or tissue culture area comprising a simulated vascular channel, a cell or a tissue and a culture medium. At least one sensor fixation area is contained at the sensor area for placing a sensor element. The present invention can be a model for stimulating cancer of specific patient to realtimely reflecting the cancer formation, transferring status and treatment strategies. The biochip could also carry testing drugs to observe how the drugs functioning to the cells/tissue as to provide a more accurate instruction of the drugs. The present invention can perform multiple test just within on chip which can save cost and also provide a more accurate test model for the patient.

Provided are: a production device by which a cell structure having a three-dimensional structure is produced using a plurality of linear members; a production system therefor; and a production method therefor. The production device 100 comprises a top plate 110, pins 120A to 120D, a first slide plate 130, a second slide plate 140, a stopper 150, a base plate 160, an outer peripheral needle-shaped member 170 and an inner peripheral needle-shaped member 180. Cell aggregates 400 are put into a three-dimensional tubular space S1 that is defined by the outer peripheral needle-shaped member 170 and the inner peripheral needle-shaped member 180. Then, the top plate 110 is pressed downward on the accumulated cell aggregates 400. Thus, the cell aggregates 400 are immersed in a culture solution 210 and stuck together so that a tubular cell structure 500 is produced using the three-dimensional space S1 as a mold.

Aspects of the present invention relate to the recombinant production of a mature complement system protein. Certain embodiments of the present invention relate to recombinant production of fully mature human complement Factor I protein (CFI). Included herein are details of an expression vector with which to recombinantly express fully mature human CFI from mammalian cells. Further disclosed are chromatography steps with which to purify recombinantly expressed CFI. Certain aspects of the present invention relate to the use of an expression system in gene therapy and the like. Certain embodiments of the present invention relate to use of said vector as a medicament, for example for use in the treatment of complement-mediated disorders.

The invention discloses a bioreactor with a vessel defining an inner volume, agitation means and at least one addition tube, wherein a delivery orifice in the addition tube is located within the inner volume and a check valve is arranged in proximity of the delivery orifice for allowing flow of a fluid in the direction from the addition tube into the inner volume of the vessel and blocking flow in the reverse direction.

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.